Why the study?
Does institutional experience (number of cases) improve device success and reduce adverse events in patients undergoing transfemoral transcatheter aortic valve replacement?
Does institutional experience (number of cases) improve device success and reduce adverse events in patients undergoing transfemoral transcatheter aortic valve replacement?
Answers are grounded in this paper and cite their sources.
A consistent low risk of adverse events in TF-TAVR is achieved after approximately 26 cases, though improved results over time were related to changes in patient risk profiles rather than technical learning curves.
OBJECTIVES: To identify number of cases needed to maximize device success and minimize adverse events after transfemoral transcatheter aortic valve replacement (TF-TAVR), and determine if adverse events were linked to the technical performance learning curve. BACKGROUND: TF-TAVR is a complex procedure with an incompletely characterized learning curve for clinical outcomes. METHODS: From 4/2007-2/2012, 1521 patients underwent TF-TAVR in the PARTNER-I trial. Outcomes learning curves were defined as number of cases needed to reach a plateau for device success, adverse events, and post-procedure length of stay. Institutional variation was accounted for by mixed-model non-linear techniques, which were also used to identify contribution of the procedure time learning curve to 30-day major adverse events and length of stay. RESULTS: Eighty percent device success was achieved after 22 cases; major vascular complications fell below 5% after 70 cases and major bleeding below 10% after 25 cases. It took an average of 28 cases to achieve a consistent low risk of 30-day major adverse events, but institutions entering in the middle of the trial achieved it after about 26. The most significant correlate of 30-day major adverse events and post-procedure length of stay was procedure time (P < 0.0001). However, this association was related to patient and unmeasured variables, not the procedure time learning curve (P = 0.6). CONCLUSIONS: By end of trial, a consistent low risk of adverse events was achieved after ∼26 cases. However, these improved results were due to change in patient risk profile; outcomes were not linked to the technical performance learning curve.
No takes yet. Share an insight, caveat, or question.
Minha et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: